Search

Hematopoietic stem cell (HSC) multipotency and self-renewal are typically defined through serial transplantation experiments. Host conditioning is necessary for robust HSC engraftment, likely by reducing immune-mediated rejection and by clearing limited HSC niche space. Because irradiation of the recipient mouse is non-specific and broadly damaging, there is a need to develop alternative models to study HSC performance at steady-state and in the absence of radiation-induced stress. We have generated and characterized two new mouse models where either all hematopoietic cells or only HSCs can be specifically induced to die in vivo or in vitro. Hematopoietic-specific Vav1-mediated expression of a loxP-flanked diphtheria-toxin receptor (DTR) renders all hematopoietic cells sensitive to diphtheria toxin (DT) in "Vav-DTR" mice. Crossing these mice to Flk2-Cre mice results in "HSC-DTR" mice which exhibit HSC-selective DT sensitivity. We demonstrate robust, rapid, and highly selective cell ablation in these models. These new mouse models provide a platform to test whether HSCs are required for long-term hematopoiesis in vivo, for understanding the mechanisms regulating HSC engraftment, and interrogating in vivo hematopoietic differentiation pathways and mechanisms regulating hematopoietic homeostasis., (© 2022. The Author(s).)

Platelets are the terminal progeny of megakaryocytes, primarily produced in the bone marrow, and play critical roles in blood homeostasis, clotting, and wound healing. Traditionally, megakaryocytes and platelets are thought to arise from multipotent hematopoietic stem cells (HSCs) via multiple discrete progenitor populations with successive, lineage-restricting differentiation steps. However, this view has recently been challenged by studies suggesting that (1) some HSC clones are biased and/or restricted to the platelet lineage, (2) not all platelet generation follows the "canonical" megakaryocytic differentiation path of hematopoiesis, and (3) platelet output is the default program of steady-state hematopoiesis. Here, we specifically investigate the evidence that in vivo lineage tracing studies provide for the route(s) of platelet generation and investigate the involvement of various intermediate progenitor cell populations. We further identify the challenges that need to be overcome that are required to determine the presence, role, and kinetics of these possible alternate pathways.

Hematopoiesis changes upon aging, including expansion of hematopoietic stem cells (HSCs) and megakaryocyte progenitors (MkPs), which undergo changes in phenotype and function. Platelets, the progeny of MkPs, also undergo age-related alterations that drive inflammation and cardiovascular and thrombotic disease; major health concerns. We discovered a non-canonical (ncMkP) population that specifically expands upon aging. Compared to their canonical (cMkP) counterparts, ncMkPs exhibit increased expansion and survival with age. Upon transplantation and serial blood assessment, both young and old cMkPs, and young ncMkPs, contributed to similar levels of platelet formation. In contrast, aged ncMkPs specifically produced greater platelet output. The progressive increase in ncMkPs with age appears to be, in part, originating from HSCs as in vitro generation of ncMkPs was significantly enhanced by aged compared to young HSCs. Further, single-cell functional analysis revealed that this was not driven by individual HSC clones, a finding substantiated by single-cell RNA sequencing of young and old bone marrow (BM). Progressively increasing, chronic inflammation is thought to be a driver of aging. Inducing chronic inflammation in young mice partially phenocopies known features of aged mice, including altered platelet output and expanded HSC numbers, implicating its role in influencing age-related platelet production. Direct assessment of inflammatory modulation of young and old HSCs, cMkPs, and ncMkPs via in vitro culture revealed distinct age- and population-specific responses, uncovering surprisingly distinct and differential roles for direct inflammatory reprogramming. These new data provide mechanistic insight to cell-based causes of aging-related adverse thrombotic events and may offer targets for mitigation and rejuvenation. [ABSTRACT FROM AUTHOR]

• A perspective on the first in vivo clonal stem cell assay is provided. • The self-renewal and differentiation capacity of spleen colony-forming cells is discussed • Technology boosts the resolution and throughput of CFU-S assays. • The current day value of CFU-S assessment is determined. Hematopoietic stem cells (HSCs) have been studied extensively since their initial functional description in 1961 when Dr. James Till and Dr. Ernest McCulloch developed the first in vivo clonal strategy, termed the spleen colony-forming unit (CFU-S) assay, to assess the functional capacity of bone marrow–derived hematopoietic progenitors at the single-cell level. Through transplantation of bone marrow cells and analysis of the resulting cellular nodules in the spleen, the CFU-S assay revealed both the self-renewal and clonal differentiation capacity of hematopoietic progenitors. Further development and use of this assay have identified highly proliferative, self-renewing, and differentiating HSCs that possess clonal, multilineage differentiation. The CFU-S strategy has also been adapted to interrogating single purified hematopoietic stem and progenitor cell populations, advancing our knowledge of the hematopoietic hierarchy. In this review, we explore the major discoveries made with the CFU-S assay, consider its modern use and recent improvements, and compare it with commonly used long-term transplantation assays to determine the continued value of the CFU-S assay for understanding HSC biology and hematopoiesis. [Display omitted] [ABSTRACT FROM AUTHOR]